secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2026-07-01T11:17:08+00:00
Accession:  0001628280-26-046340
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PBGENE-HBV shows 1-log cccDNA reduction; DMD trial activates second site
------------------------------------------------------------------------

- PBGENE-HBV in ELIMINATE-B study demonstrated 1-log (10-fold) reduction in cccDNA-derived transcripts from liver biopsy.
- Company targets year-end 2026 for next program update on chronic hepatitis B.
- FUNCTION-DMD trial for Duchenne muscular dystrophy activated second clinical site at Washington University in St. Louis.
- Initial safety data from DMD trial targeted for year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026046340/0001628280-26-046340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026046340/dtil-20260701.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-046340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer